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The renineangiotensin system (RAS) plays pivotal roles in homeostasis, but its abnormal activation has
been proposed as a risk factor for several disorders including diabetes. Using animal models, we pre-
viously clariﬁed the molecular mechanisms in which tissue RAS stimulates retinal angiogenesis and the
critical roles of (pro)renin receptor [(P)RR] in retinal RAS activation and its concurrent intracellular signal
transduction, i.e., the receptor-associated prorenin system (RAPS). Most recently, we have revealed that
(P)RR is associated with vascular endothelial growth factor (VEGF)-driven angiogenic activity in human
proliferative diabetic retinopathy (DR), and also showed a close relationship between vitreous renin
activity and VEGF-induced pathogenesis of DR. These ﬁndings suggest that both vitreous RAS and retinal
RAPS are tightly linked to the molecular pathogenesis of DR.
Copyright  2013, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Diabetic retinopathy (DR) is a leading cause of severe vision loss
and blindness in developed countries. Proliferative DR (PDR), the
advanced stage of DR, is characterized by proliferation of ﬁbro-
vascular tissue formed by the extension of retinal angiogenesis into
the vitreous cavity, and formation of the ﬁbrovascular tissue results
in severe complications, such as tractional retinal detachment and
vitreous hemorrhage. Of the numerous cytokines and growth fac-
tors involved in the molecular pathogenesis of DR, vascular endo-
thelial growth factor (VEGF) has been considered the major
proinﬂammatory and angiogenic factor in PDR.1e3 VEGF plays
crucial roles in diverse physiological processes such as embryo-
genesis, endometrial maturation, andwound healing; however, it is
also associated with various pathological events including diabetes
and cancer. Tumor growth requires new vessel formation, which is
driven predominantly by VEGF, the most potent angiogenic factor
and the principal molecular target for anti-angiogenic therapy.4 We
also revealed a signiﬁcant contribution of VEGF165 isoform to
angiogenic activity in PDR, showing that ﬁbrovascular tissues co-
expressing VEGF receptor (VEGFR)-2 and neuropilin (NRP) 1, the
speciﬁc receptor for VEGF165, are highly vascularized.5e7 VEGFology, Hokkaido University
ku, Sapporo 060-8638, Japan.
ida).
e Ophthalmologic Society of Taiwincreases the expression of adhesion molecules and subsequently
stimulates leukocyte inﬁltration, leading to the development of
retinal angiogenesis and ﬁbrovascular proliferation.5e7
The renineangiotensin system (RAS) has traditionally been
regarded as a key regulatory mechanism for sodium and ﬂuid ho-
meostasis and, thus, controlling systemic blood pressure (i.e., cir-
culatory RAS). Recently, the existence of a local RAS has been
established in various organs including the brain, eye, heart, liver,
and kidney (i.e., tissue RAS).8 Tissue RAS acts in a paracrine fashion
and regulates various biological and pathological events such as cell
signaling, apoptosis, proliferation, angiogenesis, immune re-
sponses, and extracellular matrix formation.9e11 In this review, we
will focus on the relationship of DR and tissue RAS, and suggest a
novel concept for the molecular pathogenesis of tissue RAS in the
vitreous, referred to as “vitreous RAS”, which was also supported by
and compatible with several other reports on DR.2. Vitreous RAS is associated with the receptor-associated
prorenin system in DR
Several types of organ damage are known to result from acti-
vation of tissue RAS. As concerns its relationship with the eye,
pharmacological blockade of angiotensin converting enzyme
or angiotensin II type 1 receptor (AT1R) resulted in beneﬁcial
effects on the incidence and progression of DR in several clinical
trials including the EURODIAB Controlled Trial of Lisinopril inan. Published by Elsevier Taiwan LLC. All rights reserved.
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Candesartan Trials (DIRECT)-Prevent 1, -Protect 1, and -Protect 2,
and the RAS study.12e15 We elucidated the molecular mechanisms in
which tissue RAS causes retinal inﬂammation and angiogenesis in the
murine model of endotoxin-induced uveitis, streptozotocin-induced
diabetes, and laser-induced choroidal neovascularization16e18 and
the critical role of (pro)renin receptor [(P)RR] in retinal RAS activa-
tion.19e22 (P)RR binds with prorenin to exert renin activity through
the conformational change of the prorenin (nonproteolytic activation
of prorenin causing tissue RAS) instead of the conventional proteolysis
of the prorenin prosegment by processing enzymes (proteolytic
activation of prorenin causing circulatory RAS). In addition to tissue
RAS activation, prorenin binding to (P)RR also activates RAS-
independent signal transduction including the extracellular signal-
regulated kinase (ERK) pathway, which has been shown to
contribute to organ damage. The (P)RR-mediated dual activation of
tissue RAS and RAS-independent signaling pathways, referred to as
the receptor-associated prorenin system (RAPS), was shown to be
involved in the molecular pathogenesis of ocular disorders including
retinal inﬂammation and choroidal neovascularization,20e23 both of
which are required for the upregulated expression of VEGF down-
stream of the retinal and choroidal RAPS, respectively.
Interestingly, (P)RR was reported to undergo cleavage by pro-
teases to generate a soluble form of (P)RR [s(P)RR] that retains its
capability for nonproteolytic activation of prorenin, causing the
conversion of angiotensinogen to angiotensin I in vitro.24 We
recently have shown that s(P)RR, prorenin, activated prorenin,
VEGF, and renin activity levels in vitreous ﬂuids were signiﬁcantly
higher in PDR eyes than in nondiabetic control eyes.25,26 Increased
s(P)RR levels in PDR eyes, released from neovascular endothelial
cells in ﬁbrovascular tissues, were signiﬁcantly correlated with
vitreous prorenin, activated prorenin, and VEGF levels and theFig. 1. Molecular mechanisms in (A) the vitreous renineangiotensin system (RAS) and (B) the
factor (VEGF)-driven pathogenesis of diabetic retinopathy (DR). The vitreous RAS is caused by
(P)RR. ACE ¼ angiotensin-converting enzyme; AGT ¼ angiotensinogen; Ang I ¼ angiotensin I;
regulated kinase; NF-kB ¼ nuclear factor-kB; (P)RR ¼ (pro)renin receptor. Note. From “Vitreou
retinopathy.” by A. Kanda, K. Noda, W. Saito, and S. Ishida, 2013, Br J Ophthalmol, 97, p. 667. Cvascular density of ﬁbrovascular tissues.25 Interestingly, renin ac-
tivity levels also signiﬁcantly correlated with the vitreous levels of
s(P)RR, prorenin, activated prorenin, and VEGF.26 These data indi-
cate that the vitreous renin activity stems from s(P)RR-mediated
nonproteolytic activation of prorenin and the signiﬁcant role of
(P)RR in the pathogenesis of PDR. Indeed, (P)RR and RAS compo-
nents were expressed in diabetic ﬁbrovascular tissues and human
retinal cell lines,25 and the vitreous levels of prorenin and angio-
tensin II were shown to be elevated in PDR eyes.27e30 Furthermore,
a close link between the vitreous renin activity and VEGF levels
validates our concept of “vitreous RAS” that contributes to the
angiogenic activity of DR. Consequently, in concert with vitreous
RAS due to s(P)RR (Fig. 1A),26 retinal RAPS due to membrane-type
(i.e., full-length) (P)RR25 (Fig. 1B) is thought to regulate VEGF
expression in DR.
Although we have shown the signiﬁcant role of (P)RR signaling
via ERK21,25 as well as AT1R signaling via nuclear factor (NF)-kB16 in
the upregulation of VEGF expression, it is difﬁcult to determine the
ratio of involvement with the angiogenic activity in human PDR.
Cleavage enzymes for processing full-length (P)RR to s(P)RR include
the proprotein convertase furin31 and ADAM19 (a disintegrin and
metalloproteinase),32 both of which proved to be present in endo-
thelial cells in the ﬁbrovascular tissues in PDR.25 Gene expression
and enzymatic activity of these proteases in the neovascular
endothelial cells are likely to deﬁne the contribution ratio between
vitreous RAS and retinal RAPS. Investigation into the biochemical
regulation of furin and ADAM19 is required in the future to further
elucidate (P)RR-related molecular pathogenesis of DR.
The signiﬁcance of the pathogenic system “vitreous RAS”may be
attributed in part to a possibility of revising the current surgical
indication and concept of vitrectomy for DR. In the clinical setting,
retinal surgeons remove the vitreous from PDR eyes because of (1)retinal receptor-associated prorenin system (RAPS) leading to vascular endothelial growth
soluble (pro)renin receptor [s(P)RR], whereas retinal RAPS is required for membrane-type
Ang II ¼ angiotensin II; AT1R ¼ angiotensin II type 1 receptor; ERK ¼ extracellular signal-
s renin activity correlates with vascular endothelial growth factor in proliferative diabetic
opyright 2013, BMJ Publishing Group. Adapted with permission.
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visual axis and (2) tractional retinal detachment inwhich the retina
is elevated by the vitreous that functions as the scaffold of the
ﬁbrovascular proliferative tissue originating from retinal vessels.
These two major classic indications to the advanced stages have
long been applied in terms of a mechanical or physical cue. By
contrast, our data on vitreous renin activity indicate the possibility
of the vitreous per se as the ampliﬁer of themolecular pathogenesis
of PDR. Retinal surgeons frequently encounter surgical cases where
diabetic macular edema, a consequence of VEGF-induced vascular
hyperpermeability, is diminished soon after vitrectomy. This is
explained at least in part by the pathological concept of vitreous
RAS, the driving force of the downstream AT1R/NF-kB/VEGF axis
responsible for the pathogenesis of DR (Fig. 1A). It is reasonable,
therefore, to think that the vitreous is not just the reservoir of
detrimental cytokines but the pathogenic factory of RAS compo-
nents. In this sense, the vitrectomy procedure harbors a biochem-
ical implication, which may expand the current surgical strategy to
earlier intervention for broader indications to reduce the vitreous
RAS-derived production capability of VEGF and other several
cytokines.
3. Conclusion
These recent data suggest a close association of vitreous RAS and
retinal RAPS with VEGF-induced pathogenesis of DR. Our ﬁndings
may not only lead to a better understanding of the molecular
pathogenesis of DR, but also activate the clinical research in the
surgical point of view, thus contributing to further improvement of
visual prognosis in patients with DR.
Acknowledgments
This work was supported in part by the Matching Program for
Innovations in Future Drug Discovery and Medical Care, Takeda
Science Foundation, SuzukenMemorial Foundation, and a grant-in-
aid from the Ministry of Education, Science, and Culture of Japan
(AK #24791823).
References
1. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, et al.
Increased vascular endothelial growth factor levels in the vitreous of eyes with
proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445e50.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular
endothelial growth factor in ocular ﬂuid of patients with diabetic retinopathy
and other retinal disorders. N Engl J Med 1994;331:1480e7.
3. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, et al.
Detection of vascular endothelial growth factor messenger RNA and vascular
endothelial growth factor-like activity in proliferative diabetic retinopathy.
Arch Ophthalmol 1994;112:1476e82.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
et al. Bevacizumab plus irinotecan, ﬂuorouracil, and leucovorin for metastatic
colorectal cancer. N Engl J Med 2004;350:2335e42.
5. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, et al. VEGF164
is proinﬂammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:
2155e62.
6. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, et al. VEGF164-
mediated inﬂammation is required for pathological, but not physiological,
ischemia-induced retinal neovascularization. J Exp Med 2003;198:483e9.
7. Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, et al. VEGF164(165) as
the pathological isoform: differential leukocyte and endothelial responses
through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45:368e74.
8. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems.
Physiol Rev 2006;86:747e803.9. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy.
Carcinogenesis 2008;29:1675e84.
10. Ramalho FS, Ramalho LN, Castro-e-Silva Junior O, Zucoloto S, Correa FM. Effect
of angiotensin-converting enzyme inhibitors on liver regeneration in rats.
Hepatogastroenterology 2002;49:1347e51.
11. Yayama K, Miyagi R, Sugiyama K, Sugaya T, Fukamizu A, Okamoto H. Angio-
tensin II regulates liver regeneration via type 1 receptor following partial
hepatectomy in mice. Biol Pharm Bull 2008;31:1356e61.
12. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A,
et al. Effect of lisinopril on progression of retinopathy in normotensive people
with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of
Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28e31.
13. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of
candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Pro-
tect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.
Lancet 2008;372:1394e402.
14. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of
candesartan on progression and regression of retinopathy in type 2 diabetes
(DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:
1385e93.
15. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and
retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med
2009;361:40e51.
16. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, et al. Suppression
of diabetes-induced retinal inﬂammation by blocking the angiotensin II type 1
receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol
Vis Sci 2007;48:4342e50.
17. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, et al. Selective sup-
pression of pathologic, but not physiologic, retinal neovascularization by
blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005;46:
1078e84.
18. Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, et al. Angiotensin II
type 1 receptor-mediated inﬂammation is required for choroidal neo-
vascularization. Arterioscler Thromb Vasc Biol 2006;26:2252e9.
19. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, et al. Role of
nonproteolytically activated prorenin in pathologic, but not physiologic, retinal
neovascularization. Invest Ophthalmol Vis Sci 2007;48:422e9.
20. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro)renin
receptor promotes choroidal neovascularization by activating its signal trans-
duction and tissue renin-angiotensin system. Am J Pathol 2008;173:1911e8.
21. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro)
renin receptor-mediated signal transduction and tissue renin-angiotensin
system contribute to diabetes-induced retinal inﬂammation. Diabetes
2009;58:1625e33.
22. Satofuka S, Ichihara A, Nagai N, Yamashiro K, Koto T, Shinoda H, et al.
Suppression of ocular inﬂammation in endotoxin-induced uveitis by inhib-
iting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci
2006;47:2686e92.
23. Satofuka S, Kanda A, Ishida S. Receptor-associated prorenin system in the
pathogenesis of retinal diseases. Front Biosci 2012;4:1449e60.
24. Biswas KB, Nabi AN, Arai Y, Nakagawa T, Ebihara A, Ichihara A, et al. Qualitative
and quantitative analyses of (pro)renin receptor in the medium of cultured
human umbilical vein endothelial cells. Hypertens Res 2010;34:735e9.
25. Kanda A, Noda K, Saito W, Ishida S. (Pro)renin receptor is associated with
angiogenic activity in proliferative diabetic retinopathy. Diabetologia 2012;55:
3104e13.
26. Kanda A, Noda K, Saito W, Ishida S. Vitreous renin activity correlates with
vascular endothelial growth factor in proliferative diabetic retinopathy. Br J
Ophthalmol 2013;97:666e8.
27. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E,
et al. Renin, prorenin, and immunoreactive renin in vitreous ﬂuid from eyes
with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160e7.
28. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular
endothelial growth factor in the vitreous ﬂuid of patients with proliferative
diabetic retinopathy. Br J Ophthalmol 2002;86:311e5.
29. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vit-
reous proteome in diabetes without diabetic retinopathy and diabetes with
proliferative diabetic retinopathy. J Proteome Res 2008;7:2516e25.
30. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, et al.
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral
vascular permeability through prekallikrein activation. Nat Med 2007;13:
181e8.
31. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form
of the (pro)renin receptor generated by intracellular cleavage by furin is
secreted in plasma. Hypertension 2009;53:1077e82.
32. Yoshikawa A, Aizaki Y, Kusano K, Kishi F, Susumu T, Iida S, et al. The (pro)renin
receptor is cleaved by ADAM19 in the Golgi leading to its secretion into
extracellular space. Hypertens Res 2011;34:599e605.
